专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130189226A1 RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS 有权
标题翻译：重组人类干扰素蛋白
公开(公告)号：US20130189226A1
公开(公告)日：2013-07-25
申请号：US13841679
申请日：2013-03-15
申请人： Haitao WANG , Chunsheng MAO , Jizhi LI , Ling WANG , Yong DU , Longbin LIU , Jing XU , Rui ZHANG
发明人： Haitao WANG , Chunsheng MAO , Jizhi LI , Ling WANG , Yong DU , Longbin LIU , Jing XU , Rui ZHANG
IPC分类号： C07K14/56
CPC分类号： C07K14/56 , A61K38/00 , C07K14/555
摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human inteferon like alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
摘要翻译：本申请涉及重组人类干扰素样蛋白。在一个实施方案中，描述了与天然存在的人类干扰素如α2b（HuIFN-α2b）相比，通过基因改组技术产生的重组蛋白具有增强的抗病毒和抗增殖活性。本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

2. 发明申请

US20100129904A1 RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS 有权
公开(公告)号：US20100129904A1
公开(公告)日：2010-05-27
申请号：US12555762
申请日：2009-09-08
申请人： Haitao WANG , Chunsheng MAO , Jizhi LI , Jing XU , Rui ZHANG , Ling WANG , Yong DU , Longbin LIU
发明人： Haitao WANG , Chunsheng MAO , Jizhi LI , Jing XU , Rui ZHANG , Ling WANG , Yong DU , Longbin LIU
IPC分类号： C12N5/10 , C07H21/04 , C12N15/63 , C12N1/21
CPC分类号： C07K14/56 , A61K38/00 , C07K14/555
摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

3. 发明授权

US07868151B2 Recombinant human interferon-like proteins 有权
标题翻译：重组人干扰素样蛋白
公开(公告)号：US07868151B2
公开(公告)日：2011-01-11
申请号：US12555762
申请日：2009-09-08
申请人： Haitao Wang , Chunsheng Mao , Jizhi Li , Jing Xu , Rui Zhang , Ling Wang , Yong Du , Longbin Liu
发明人： Haitao Wang , Chunsheng Mao , Jizhi Li , Jing Xu , Rui Zhang , Ling Wang , Yong Du , Longbin Liu
IPC分类号： C07H21/04 , A61K38/15 , C07K14/00 , C12P21/02
CPC分类号： C07K14/56 , A61K38/00 , C07K14/555
摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
摘要翻译：本申请涉及重组人类干扰素样蛋白。在一个实施方案中，与天然存在的人类干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

4. 发明申请

US20080312148A1 RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS 有权
标题翻译：重组人类干扰素蛋白
公开(公告)号：US20080312148A1
公开(公告)日：2008-12-18
申请号：US11764786
申请日：2007-06-18
申请人： Haitao Wang , Chunsheng Mao , Jizhi Li , Jing Xu , Rui Zhang , Ling Wang , Yong Du , Longbin Liu
发明人： Haitao Wang , Chunsheng Mao , Jizhi Li , Jing Xu , Rui Zhang , Ling Wang , Yong Du , Longbin Liu
IPC分类号： A61K38/21 , A61P35/00 , C07K14/00 , C12N1/19 , C12N1/21 , C12N15/11 , C12N15/63 , C12N5/10
CPC分类号： C07K14/56 , A61K38/00 , C07K14/555
摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
摘要翻译：本申请涉及重组人类干扰素样蛋白。在一个实施方案中，与天然存在的人干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

5. 发明授权

US08425895B2 Recombinant human interferon-like proteins 有权
标题翻译：重组人干扰素样蛋白
公开(公告)号：US08425895B2
公开(公告)日：2013-04-23
申请号：US12665682
申请日：2007-06-22
申请人： Haitao Wang , Chunsheng Mao , Jizhi Li , Ling Wang , Yong Du , Longbin Liu , Jing Xu , Rui Zhang
发明人： Haitao Wang , Chunsheng Mao , Jizhi Li , Ling Wang , Yong Du , Longbin Liu , Jing Xu , Rui Zhang
IPC分类号： A61K38/21 , C07K14/00 , C08H1/02 , C12P21/04 , C07H21/04 , A61K38/00
CPC分类号： C07K14/56 , A61K38/00 , C07K14/555
摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID NO: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
摘要翻译：本申请涉及重组人类干扰素样蛋白。在一个实施方案中，与天然存在的人干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

6. 发明授权

US07625555B2 Recombinant human interferon-like proteins 有权
标题翻译：重组人干扰素样蛋白
公开(公告)号：US07625555B2
公开(公告)日：2009-12-01
申请号：US11764786
申请日：2007-06-18
申请人： Haitao Wang , Chunsheng Mao , Jizhi Li , Jing Xu , Rui Zhang , Ling Wang , Yong Du , Longbin Liu
发明人： Haitao Wang , Chunsheng Mao , Jizhi Li , Jing Xu , Rui Zhang , Ling Wang , Yong Du , Longbin Liu
IPC分类号： A61K38/21 , C07K14/00 , C08H1/02 , C12P21/04 , C07H21/04 , A61K38/00
CPC分类号： C07K14/56 , A61K38/00 , C07K14/555
摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
摘要翻译：本申请涉及重组人类干扰素样蛋白。在一个实施方案中，与天然存在的人干扰素α2b（HuIFN-α2b）相比，描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

7. 发明申请

US20100303759A1 RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS 有权
公开(公告)号：US20100303759A1
公开(公告)日：2010-12-02
申请号：US12665682
申请日：2007-06-22
申请人： Haitao Wang , Chunsheng Mao , Jizhi Li , Ling Wang , Yong Du , Longbin Liu , Jing Xu , Rui Zhang
发明人： Haitao Wang , Chunsheng Mao , Jizhi Li , Ling Wang , Yong Du , Longbin Liu , Jing Xu , Rui Zhang
IPC分类号： A61K38/21 , C07H21/04 , C12N15/63 , C12N5/10 , C07K14/555 , A61P35/04 , A61P31/12
CPC分类号： C07K14/56 , A61K38/00 , C07K14/555
摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式